Научно-практический журнал
[About us] Journal 'Cytokines & Inflammation'

197376, Санкт-Петербург, ул. Акад. Павлова, д. 12,
Институт экспериментальной медицины РАМН
Тел.: (812) 543 52 14, +7 921 984 11 30, +7 921 909 55 49
Факс: (812) 543 52 14
E-mail:
Web: www.cytokines.ru


  


Year 2018
1-4 issues

About journal

Current year
Archive

Columns
Subscription

Rules for authors

Contact us

Search

Site map

Our partners:
Русский языкEnglish language
Site map Contact us

Contents | Next article | Previous article

Journal 'Cytokines & inflammation', 2009, No. 1

Subscribe for 2019 year

Order this issue

Order PDF of this article

Practitioner Advisor

Number 1'2009

NEW APPROACHES TO TREATMENT OF CERVICAL PRE-CANCER AND CANCER

A.L. Chernyshova, L.A. Kolomiets, O.N. Churuksaeva, A.A. Litvin

Uterine cervical tumors are the only human tumors for which the HPV detection is not less than 90-95%. Currently, the use of anti-viral drugs for the complex therapy of virus-associated cervical pre-cancer and cancer is one of the prospective trends in novel approaches to the treatment of these patients. The paper presents the results of the study conducted at the Gynecology Department of the Tomsk Cancer Research Institute. The study included 50 patients with virus-associated cervical pre-cancer and cancer. Treatment with Panavir resulted in complete virus elimination from the body of the patients showing a significant increase in the disease-free survival rate for cervical cancer patients and decrease in the risk of malignancy for cervical pre-cancer patients. From these observations it may be recommended to administer Panavir to all patients with virus-associated cervical pre-cancer and cancer, that would significantly improve long-term treatment results. (Cytokines and Inflammation. 2009. Vol. 8, No. 1. P. 51-53.)

Keywords: cervical cancer, virus, Panavir.

Contents | Next article | Previous article


© 2007-2019 Cytokines and inflammation